WeVote
Log In

Bill

Bill

SB 773

Relating to assaults committed against corrections officers.

2025 Regular Session Introduced by Todd Nash

MD SB 773 counts third‑party payments toward patient cost‑sharing for certain drugs by insurers/PBMs; ERISA plans excluded; effective 1/1/2026; ends 7/1/2029.

In committee upon adjournment.
0
WeVote Research Nonpartisan
Bill Summary · SB 773

SB 773 — Health Benefit Plans: Calculation of Cost‑Sharing Contribution — Summary (Chapter 692, 2025)

Status: Approved by the Governor (Chapter 692). Introduced Jan 27, 2025; approved May 20, 2025. Effective date / application: provisions take effect Jan 1, 2026 and apply to policies/contracts issued, delivered, or renewed on or after that date (fiscal note). The fiscal note also states the Act terminates July 1, 2029.

Purpose / intent

To prevent “accumulator” or similar programs from denying patients credit for third‑party financial assistance (copay coupons, manufacturer discounts, vouchers, patient assistance) when carriers calculate an enrollee’s contribution toward coinsurance, copayments, deductibles, or out‑of‑pocket (OOP) maximums for certain prescription drugs. The bill seeks to improve medication access and adherence by ensuring patient and third‑party payments reduce patients’ cost‑sharing obligations.

Key provisions

  • Scope: Applies to insurers, nonprofit health service plans, health maintenance organizations (HMOs), carriers, administrators, and pharmacy benefits managers (PBMs) that provide coverage in Maryland. Does not apply to health benefit plans subject to ERISA (self‑funded employer plans).

  • Counting assistance toward cost‑sharing: When calculating an insured’s/enrollee’s contribution to coinsurance, copayment, deductible, or OOP maximum, carriers/PBMs/administrators must include any discount, financial assistance payment, product voucher, or other out‑of‑pocket expense paid by or on behalf of the enrollee for a prescription drug that:

    • Is covered under the enrollee’s benefit plan; and
    • Either (a) has no AB‑rated generic equivalent or preferred interchangeable biosimilar, or (b) is a brand drug for which coverage was obtained via prior authorization, step therapy exception, or appeal.

  • High‑deductible health plans (HSA‑eligible HDHPs): The requirement does not apply to the HDHP deductible until the enrollee has satisfied the minimum deductible required under federal law; for preventive services, the rule applies regardless.

  • Third‑party notifications and limitations:

    • A person who provides financial assistance that is used in the cost‑sharing calculation must notify the enrollee within 7 days after acceptance of the assistance of (1) the maximum dollar amount of the assistance and (2) the assistance’s expiration date.
    • Third parties may not condition assistance on the enrollee taking certain actions (as specified in the law).

  • Carrier conduct restrictions: Carriers, administrators, and PBMs may not directly or indirectly set, alter, implement, or condition benefit design or plan terms based on information about the availability or amount of financial or product assistance for a prescription drug. This prohibition does not prevent carriers from using rebates in benefit design.

  • Enforcement: Violations may be treated as violations of the Maryland Consumer Protection Act (MCPA); the Insurance Commissioner may adopt implementing regulations.

Who is affected

  • Positively affected: Patients using copay assistance, manufacturer coupons, or other third‑party help for eligible prescription drugs — they will get credit toward deductibles and OOP maximums.
  • Regulated entities: Insurers, nonprofit health plans, HMOs, administrators, and PBMs operating in Maryland must change cost‑sharing calculations and disclosure practices.
  • Exclusions/limitations: Federal ERISA‑governed self‑insured employer plans are generally excluded. HSA‑eligible HDHP deductible treatment is limited until minimum deductible satisfied.

Fiscal and policy impacts

  • Fiscal note: Minimal administrative/fiscal impact to Maryland Insurance Administration (one-time $125 filing fee in FY 2026); additional workload absorbable. Local governments and employers that buy fully insured plans could see premium/cost changes if carriers adjust pricing to reflect counting of third‑party payments. Small businesses: minimal effect. The federal ACA annual cost‑sharing limits remain applicable (contextual reference in fiscal analysis).

Implementation and timeline

  • Effective application to new/renewed policies: Jan 1, 2026 (per fiscal note).
  • Regulatory implementation: Insurance Commissioner authorized to adopt regulations to implement the law.
  • Termination (per fiscal note): July 1, 2029 (check final statute text for any legislative changes to termination).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.